Cooper Companies Downgraded to 'Neutral' Rating

Rothschild & Co Redburn cites $85 target price for medical device company

Published on Mar. 4, 2026

Got story updates? Submit your updates here. ›

Cooper Companies (NASDAQ:COO), a global medical device company, was downgraded from a 'buy' rating to a 'neutral' rating by analysts at Rothschild & Co Redburn. The firm also set a $85.00 target price for the company's stock, indicating a potential upside of 1.96% from the previous close.

Why it matters

This downgrade from a major investment firm could impact investor sentiment and the stock price of Cooper Companies, which is a significant player in the vision care and women's health products markets. The revised rating and target price reflect Rothschild & Co Redburn's updated assessment of the company's growth prospects and competitive positioning.

The details

In their report, Rothschild & Co Redburn cited a number of factors that led to the downgrade, including concerns about the company's ability to maintain its market share and profitability in the face of increasing competition. The analysts also noted that Cooper Companies' recent acquisitions and product launches have not yet translated into significant revenue growth.

  • The downgrade was issued on Wednesday, March 4, 2026.

The players

Cooper Companies

A global medical device company headquartered in San Ramon, California, that develops, manufactures, and markets a range of vision care and women's health products.

Rothschild & Co Redburn

A leading investment firm that provides research and advisory services to institutional investors.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

This downgrade highlights the competitive challenges facing Cooper Companies as it seeks to maintain its market position in the medical device industry. Investors will be closely watching the company's performance and strategic initiatives in the coming months to see if it can regain the confidence of analysts and continue its growth trajectory.